جست‌وجوی استاد و پژوهشگر

Neveen Saidمشاهده پروفایل

دانشیار

• Cancer/oncogenesis
• Cell growth and differentiation
• Tumor microenvironment
• +۸ مورد دیگر

Neveen Said, MD, PhD, is an Associate Professor in the departments of Cancer Biology, Pathology, and Urology at Wake Forest University School of Medicine. She directs the Neveen Said Lab, which focuses on understanding tumor heterogeneity and the role of matricellular proteins in cancer progression and metastasis. Her work integrates genomic, proteomic, and metabolomic approaches with bioinformatics and genetically engineered models. MBBCh, Cairo University, 1987 MSc, Cairo University, 1992 MD, Cairo University, 1997 Her research interests include: Tumor microenvironment dynamics Metastasis suppression mechanisms Matricellular protein signaling (e.g., SPARC, RhoGDI2) Tumor-stromal interactions Metabolomic profiling of cancer Personalized cancer therapy biomarkers Her recent work emphasizes spatial metabolomics in bladder cancer, platinum-resistant ovarian cancer, and SPARC's role in tumor inflammation. She is affiliated with the Center for Redox Biology and Medicine, Comprehensive Cancer Center, and Sticht Center for Healthy Aging and Alzheimer’s Prevention.

Derek Allisonمشاهده پروفایل

دانشیار

• Cytopathology
• Molecular surgical pathology
• Cancer metabolism
• +۷ مورد دیگر

Derek Allison, MD, is Associate Professor of Pathology and Laboratory Medicine at the University of Kentucky College of Medicine, Vice-Chair for Research, Assistant Director of the Biospecimen Procurement & Translational Pathology Shared Resource, and Director of the Molecular Tumor Board at the Markey Cancer Center. His federally funded translational program bridges high-volume cytopathology service with multi-omic cancer metabolism, glycomics, and AI-driven predictive biomarkers. Education & Training: BS Biochemistry, Lipscomb University (2010) MD, Georgetown University (2014) AP/CP Residency, Johns Hopkins University School of Medicine (2018) Cytopathology Fellowship, Johns Hopkins University School of Medicine (2019) Research Focus: Dr. Allison’s group uses spatial mass-spectrometry imaging, single-cell sequencing, and machine learning to decode metabolic heterogeneity in lung and prostate cancers. Major themes include glycogen and N-glycan drivers of tumor initiation, PLK1-mediated therapy resistance, and AI-powered pathology assays that predict response to intravesical BCG in high-risk bladder cancer. Recent Publication Trends: From 2021-2025 he has >60 peer-reviewed articles centered on three intersecting tracks: (1) glycomics/glycogen biology in lung adenocarcinoma and pulmonary fibrosis, (2) PLK1 and kinase signaling in prostate and lung cancers, and (3) real-world validation of AI biomarkers in urothelial malignancies. His work consistently appears in high-impact journals such as Nature Metabolism , Nature Communications , Cell Reports Medicine , and Cancer Cytopathology . Leadership & Service: He directs the Molecular Tumor Board at Markey Cancer Center, leads the BPTP biobank, and serves on multiple NCI-funded consortia for precision oncology. He mentors pathology residents, graduate students, and clinical fellows in projects spanning interventional cytopathology to computational metabolomics.

Joshua J Meeksمشاهده پروفایل

دانشیار

• Bladder Cancer
• Genetics
• Epigenetics
• +۵ مورد دیگر

Joshua J Meeks, MD, PhD is an Associate Professor of Urology, Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine and serves as Section Chief of Robotic Surgery at the Jesse Brown VA Medical Center. His clinical expertise centers on bladder cancer diagnosis, treatment, and management. Dr. Meeks completed his education and training at Northwestern University Feinberg School of Medicine, earning both MD and PhD degrees (2003-2005), followed by urology residency (2011) and urologic oncology fellowship at Memorial Sloan-Kettering Cancer Center (2012). He holds board certification in Urology from the American Board of Urology. His research focuses on epigenetic mechanisms and genetic mutations in bladder cancer biology, particularly chromatin remodeling genes and driver mutations. Current work aims to develop novel systemic and intravesical therapies to improve patient survival. Recent publications demonstrate expertise in AI-driven treatment prediction, biomarker development using urine tumor DNA, and advanced drug delivery systems like TAR-200 for sustained gemcitabine release. Research Scholar, American Urological Association Foundation (2008) Dr. Meeks leads multiple clinical trials including Phase 1/2 studies of erdafitinib intravesical delivery (TAR-210), Jelmyto registries for upper tract urothelial carcinoma, and combination therapies like BCG with ALT-803. He serves on editorial boards for Science Advances and Urologic Oncology, and holds leadership roles in ASCO, SITC, and SouthWest Oncology Group. His industry collaborations span AstraZeneca, Merck, Pfizer, and multiple biotechnology firms focused on bladder cancer therapeutics.

Jonathan Izawaمشاهده پروفایل

دانشیار

• Prostate Cancer
• Bladder Cancer
• Urologic Oncology
• +۷ مورد دیگر

Dr. Jonathan Izawa is an Associate Professor in the Department of Surgery at Western University's Schulich School of Medicine and Dentistry, with additional appointments at London Health Sciences Centre, Lawson Health Research Institute, and McGill University. He is a prominent urologic oncologist specializing in prostate and bladder cancer research. His research interests focus on active surveillance protocols for low-risk prostate cancer , clinical trials investigating metformin's role in prostate cancer management , and comparative effectiveness of surgical approaches for bladder cancer . Dr. Izawa has made significant contributions to understanding optimal radiation therapy techniques for muscle-invasive bladder cancer and the impact of histologic subtypes on treatment outcomes. Analysis of his recent publications reveals a strong emphasis on methodologically rigorous clinical research , with numerous randomized controlled trials, multi-institutional database analyses, and sophisticated statistical approaches including inverse probability treatment weighting. His work consistently addresses clinically relevant questions that directly impact patient management decisions in urologic oncology. Dr. Izawa maintains active collaborations across Canadian academic centers through the Canadian Bladder Cancer Information System (CBCIS), which includes 14 academic institutions. His research has been published in high-impact journals including the Journal of Clinical Oncology, JAMA SURGERY, and The Journal of Urology. His clinical trial work, particularly the Metformin Active Surveillance Trial (MAST), represents a significant contribution to the field of prostate cancer management. His research on radical cystectomy outcomes, pelvic lymph node dissection, and radiation therapy techniques continues to inform contemporary urologic oncology practice guidelines in Canada and internationally.

• Bladder Cancer
• Urologic Oncology
• Radical Cystectomy
• +۳ مورد دیگر

Ulla Nordström Joensen serves as a Clinical Associate Professor within the Department of Clinical Medicine at the University of Copenhagen's Faculty of Health and Medical Sciences, maintaining clinical practice through the Capital Region of Denmark (Region H). Based at Blegdamsvej 3 in Copenhagen, her work bridges academic research and clinical urology with specialized focus on bladder cancer management and treatment optimization. Her research program centers on urologic oncology with particular emphasis on radical cystectomy techniques (including retrosigmoid approaches), smoking cessation interventions for bladder cancer patients, antibiotic prophylaxis protocols, and chemotherapy optimization . She actively investigates surgical innovations and perioperative care strategies to improve oncological outcomes and quality of life for bladder cancer patients, with strong methodological diversity spanning randomized trials, observational studies, and qualitative approaches. Analysis of her 2024-2025 publications reveals consistent leadership in Danish national bladder cancer initiatives, particularly the DaBlaCa research consortium. Her work demonstrates evolving trends toward multicenter collaboration, patient-centered intervention design, and practical clinical implementation - with increasing attention to surgical technique refinement, supportive care integration, and real-world treatment protocol evaluation. The publications collectively underscore a translational research trajectory focused on immediate clinical applicability. Dr. Joensen operates within Denmark's integrated academic-clinical framework as a key contributor to the DaBlaCa studies (DaBlaCa-16, DaBlaCa-17, REINFORCE trial), which represent nationwide collaborative efforts to standardize and improve bladder cancer care through evidence-based practice. Her research group maintains strong ties with regional hospitals and national cancer registries, facilitating rapid translation of findings into clinical guidelines.

• Biomedical Research
• Cystitis, Interstitial
• Drug Delivery Systems
• +۷ مورد دیگر

Darryl T. Martin is an Assistant Professor in the Department of Urology at the Yale School of Medicine and a member of the Yale Cancer Center. His research focuses on understanding the biological factors and molecular determinants that drive cancer progression and metastasis, particularly in urologic cancers. Dr. Martin is affiliated with the Cancer Signaling Networks program and the Janeway Society at Yale, demonstrating his integration into multiple research communities within the institution. Dr. Martin received his PhD from Memorial University of Newfoundland, where he trained as a cancer molecular biologist studying tumor growth and differentiation under the supervision of Drs. Robert Gendron and Hélène Paradis. He then completed postdoctoral training with Dr. Robert M. Weiss at Yale University School of Medicine, focusing on drug delivery and cancer progression, which laid the foundation for his current research program. Dr. Martin's research program investigates three main areas: defining distant metastasis by elucidating biologic factors and molecular determinants; modulating the tumor microenvironment to transform immunosuppressive conditions into immune-activated states; and enhancing tumor targeting using surface-modified nanoparticles. His work combines molecular biology, translational science, and nanomedicine to develop novel approaches for cancer treatment, with particular emphasis on prostate and bladder cancers. Analysis of Dr. Martin's recent publication record reveals a strong translational focus, bridging basic molecular mechanisms with clinical applications. His work spans genomic testing for prostate cancer, treatment optimization for bladder cancer variants, and nanoparticle-based drug delivery systems, demonstrating both breadth and depth in urologic oncology research. Dr. Martin is an active member of several professional organizations: American Association for Cancer Research (AACR) Society for Basic Urologic Research (SBUR) American Society for Biochemistry and Molecular Biology (ASBMB) The Martin Lab is currently funded by Department of Defense (DoD) and foundation grants, supporting research on cancer progression and metastasis. Dr. Martin collaborates extensively with clinical colleagues at Yale, reflecting the interdisciplinary nature of modern cancer research and his commitment to translating laboratory discoveries into clinical applications. Dr. Martin's laboratory focuses on developing practical applications for cancer treatment, particularly through nanoparticle systems that can deliver drugs to malignant tissues with high specificity. His research represents an important bridge between basic cancer biology and clinical oncology, with potential to improve outcomes for patients with urologic malignancies.

• Medical Oncology
• Genitourinary Oncology
• Prostate Cancer
• +۷ مورد دیگر

Daniel P. Petrylak is Professor of Medicine (Medical Oncology) and Urology at Yale School of Medicine and serves as Chief of Genitourinary Oncology at Yale Cancer Center. He joined the Yale faculty in 2012 after completing his medical training, which included an MD from Case Western Reserve University School of Medicine (1985), residency and internship at Bronx Municipal Hospital, and fellowship at Memorial Sloan-Kettering Cancer Center. Dr. Petrylak is a pioneer in developing new drugs and treatments for prostate, bladder, kidney, and testicular cancers. His research focuses on translating basic science discoveries into clinical applications, with particular interest in immunotherapy advancements for genitourinary cancers. As co-director of the Signal Transduction Research Program at Yale Cancer Center, he works with approximately 40 physicians and scientists to understand how cancer stem cells are regulated and communicate with surrounding tissue. His recent publications (2024-2025) demonstrate a strong focus on novel therapeutic approaches for advanced urothelial and prostate cancers, including antibody-drug conjugates (sacituzumab govitecan, enfortumab vedotin), immunotherapy combinations, and targeted therapies. His work spans clinical trial design, biomarker analysis, and patient-reported outcomes, reflecting a comprehensive approach to improving cancer treatment. Dr. Petrylak currently serves as principal investigator or co-principal investigator on seven Southwest Oncology Group clinical trials for genitourinary cancers. He has authored more than 100 peer-reviewed articles on prostate and bladder cancer research, with recent work appearing in high-impact journals including Journal of Clinical Oncology, Cancer Discovery, and JAMA Network Open. At Smilow Cancer Hospital, Dr. Petrylak leverages his national leadership in clinical trials to provide New England patients with access to the latest investigational drugs while maintaining the highest standards of care. His philosophy emphasizes translating research breakthroughs into tangible patient benefits, as evidenced by his role in moving docetaxel therapy for advanced prostate cancer from phase I to III trials, which supported its regulatory approval.

Petros Grivasمشاهده پروفایل

استاد

• Genitourinary Oncology
• Bladder Cancer
• Urothelial Carcinoma
• +۵ مورد دیگر

Petros Grivas is a Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine and a Professor in the Clinical Research Division at Fred Hutch Cancer Center. He serves as Clinical Director of Genitourinary Oncology at UW Medicine and practices at Fred Hutch Cancer Center locations in South Lake Union and UW Medical Center – Montlake. Education: M.D., University of Patras School of Medicine, Greece Ph.D., University of Patras School of Medicine, Greece Residency, Drexel University College of Medicine Fellowship, University of Michigan, Hematology & Oncology GME Scholars Health Care Administration and Leadership Program, University of Michigan Harvard Business School Strategy for Health Care Delivery Program Dr. Grivas is an internationally renowned medical oncologist specializing in genitourinary cancers including bladder, prostate, and testicular cancer. His research focuses on developing and leading innovative clinical trials investigating immunotherapies, targeted therapies, and novel treatment approaches for urinary tract cancers. His work has contributed to FDA approvals of new drugs for treating urothelial carcinoma. His publications demonstrate deep expertise in bladder cancer biology, immunotherapy mechanisms, and clinical trial design for genitourinary malignancies. Analysis of his 308 publications spanning from 2006-2025 shows a strong focus on urothelial carcinoma, with particular emphasis on immunotherapy applications, biomarker development, and clinical trial outcomes. His research demonstrates increasing sophistication in molecular characterization of tumors and personalized treatment approaches over time. Dr. Grivas maintains active clinical practice while leading multiple research initiatives focused on improving outcomes for patients with genitourinary cancers. His work bridges translational research with direct patient care, ensuring scientific discoveries rapidly benefit patients.

Karim Chamieمشاهده پروفایل

دانشیار

• Urologic Oncology
• Bladder Cancer Research
• Robotic Surgery
• +۲ مورد دیگر

Dr. Karim Chamie is an Associate Professor of Urology at the University of California, Los Angeles (UCLA) specializing in urologic oncology with a focus on bladder cancer. He practices at Westwood Urology in Los Angeles and has hospital affiliations with Ronald Reagan UCLA Medical Center and UCLA Santa Monica Medical Center. His clinical expertise includes minimally invasive urology, robotic surgery, and comprehensive care for bladder, prostate, and kidney cancers. Dr. Chamie's educational background includes: MD from Keck School of Medicine of the University of Southern California (2003) Surgical Internship at UC Davis Health (2004) Surgical Residency at UC Davis Health (2005) Urology Residency at UC Davis Health (2009) Urologic Oncology Fellowship at UCLA School of Medicine (2012) Board Certification in Urology from the American Board of Urology (2015) Dr. Chamie's primary research interests focus on health services research and clinical trials in bladder cancer . His work examines treatment patterns, healthcare disparities, and quality of care in urologic oncology. He has a particular interest in robotic surgery applications for bladder cancer treatment and novel therapeutic approaches for non-muscle invasive and advanced bladder cancer. His research bridges clinical practice with healthcare policy to improve patient outcomes and access to care. Dr. Chamie's publication record demonstrates a strong focus on bladder cancer research, with numerous articles on clinical management, systemic therapies, and surgical innovations. His recent work emphasizes immunotherapy approaches, novel drug delivery mechanisms, and quality of care metrics in bladder cancer treatment. The trend in his publications shows increasing emphasis on translational research that connects laboratory findings with clinical applications, particularly in the areas of robotic surgery and targeted therapies for urothelial carcinoma. Dr. Chamie has received numerous professional recognitions: Top Doctors, Los Angeles Magazine (2021) Dean's Scholar, University of Southern California Keck School of Medicine Baxter Academic Scholarship Gerber Academic Scholarship Northern California Urological Association Resident Research Award (1st Place) Gerald P. Murphy Award, American Urological Association Best reviewer in 2011 Award for the Journal of Urology As an active researcher and clinician, Dr. Chamie participates in multiple clinical trials for bladder cancer treatment, including studies of intravesical enfortumab vedotin for non-muscle invasive bladder cancer and combination therapies for advanced disease. His work as a principal investigator and co-investigator demonstrates his commitment to advancing the field through rigorous clinical research. While specific grant details aren't provided in the source material, his active participation in clinical trials suggests substantial research funding support. Dr. Chamie is affiliated with the Jonsson Comprehensive Cancer Center (JCCC) at UCLA, which provides a collaborative environment for cancer research and treatment. His work involves multidisciplinary teams including medical oncologists, radiation oncologists, pathologists, and basic science researchers to develop comprehensive approaches to urologic cancers. His clinical practice at Westwood Urology serves as both a treatment center and a site for clinical research translation.

• Urology
• Oncology
• Orthopedics
• +۳ مورد دیگر

Eugen Yu-Hui Wang serves as a Tutor adviser at the Center for Clinical Research in Sörmland (CKFD), affiliated with Uppsala University through a collaboration with Region Sörmland. Based in Eskilstuna, Sweden, he conducts clinical research with emphasis on surgical outcomes and long-term patient follow-up in urology and orthopedics. His research spans bladder cancer therapeutics, prostatectomy recovery, and knee arthroplasty interventions, utilizing Swedish nationwide registries for large-scale epidemiological analysis. Key interests include BCG immunotherapy effects, dementia risk correlations, and comparative surgical techniques, reflecting a methodological focus on cohort studies and randomized controlled trials. Wang's publication timeline (2014-2023) demonstrates sustained engagement in urological oncology and orthopedic surgery, with recent work exploring dementia links to cancer treatments. His collaborations involve Uppsala University researchers and regional healthcare providers across Sweden. As a Tutor adviser at CKFD, he contributes to clinical mentorship and research coordination. The Center for Clinical Research in Sörmland functions as a regional hub for evidence-based medicine, bridging Uppsala University's academic resources with Region Sörmland's healthcare infrastructure.

Giovanni Lughezzaniمشاهده پروفایل

دانشیار

• Urology
• Prostate Cancer
• Renal Cell Carcinoma
• +۵ مورد دیگر

Giovanni Lughezzani is an Associate Professor of Urology at Humanitas University in Milan, Italy. He has held academic positions since 2013, progressing from Adjunct Professor to his current role as Associate Professor since May 2022. His clinical work is based at IRCCS Humanitas Research Hospital, where he specializes in urological cancers and minimally invasive surgical techniques. Education: Medical doctor degree (07/2007): 110 cum laude Urologist certification (03/2013): 70/70 cum laude National Academic Qualification as Associate Professor (11/2016) Dr. Lughezzani's research focuses on urological malignancies, particularly prostate cancer, renal cell carcinoma, and urinary tract cancers. His work emphasizes prognostic factors, diagnostic markers, and minimally invasive surgical approaches including robotic and laparoscopic techniques. He has made significant contributions to understanding targeted prostate cancer diagnosis and treatment of various urological conditions through endoscopic and minimally invasive methods. His publication record demonstrates consistent research activity in urological oncology, with a focus on prostate cancer diagnostics and treatment, bladder cancer management, and robotic surgical techniques. Recent work shows a shift toward comparative effectiveness research, systematic reviews, and clinical trials evaluating diagnostic and therapeutic approaches in urology. Dr. Lughezzani has authored over 170 peer-reviewed publications, demonstrating expertise across multiple subspecialties within urology. His collaborative research spans international institutions, reflecting the global nature of contemporary urological research. As an academic educator, he has contributed to medical training programs at both Vita-Salute San Raffaele University and Humanitas University, mentoring future physicians in urological care and surgical techniques.